Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial.

**Study design (if review, criteria of inclusion for studies)**

Multicentre, open-label, comparative, randomised trial

**Participants**

49 centres in Austria, France, Germany, and Italy. Eligible patients had cystic fibrosis, were older than 10 years, and had newly diagnosed diabetes.

**Interventions**

Insulin or repaglinide, stratified by sex and age (10-15 years or >15 years). 34 patients in the repaglinide group and 41 in the insulin group

**Outcome measures**

The primary outcome was glycaemic control assessed by mean change in HbA1c concentration from baseline after 24 months of treatment. Differences between groups were assessed by linear models.

**Main results**

At 24 months, glycaemic control was similar in the repaglinide and insulin groups (mean change in HbA1c concentration from baseline 0.2% [SD 0.7%], 1.7 mmol/mol [8.1 mmol/mol] with repaglinide vs -0.2% [1.3%], -2.7 mmol/mol, [14.5 mmol/mol] with insulin; mean difference between groups -0.4%, (95% CI -1.1 to 0.2 [-4.4 mmol/mol, -11.5 to 2.7], p=0.15). The most frequent adverse events were pulmonary events (43 [40%] of 107 in the repaglinide group and 60 [45%] of 133 in the insulin group), and the most frequent serious adverse events were pulmonary events leading to hospital admission (five [50%] of ten and seven [54%] of 13, respectively).

**Authors’ conclusions**

Repaglinide for glycaemic control in patients with cystic-fibrosis-related diabetes is as efficacious and safe as insulin.

http://dx.doi.org/10.1016/S2213-8587(17)30400-X

**See also**


**Keywords**

Adult; Aged; Child; Diabetes Mellitus; Gastrointestinal Diseases; Hypoglycemic Agents; Insulin; Pancreatic Diseases; pharmacological intervention; Repaglinide;